Adicet Bio Inc

NASDAQ ACET

Data sourced from

and

Download Data

Adicet Bio Inc Gross Profit 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -64.59%

Adicet Bio Inc Gross Profit 2 year CAGR is -64.59% for the Trailing 12 Months (TTM) ending March 31, 2024. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Adicet Bio Inc Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -24.99 M, a -163.66% change year over year.
Adicet Bio Inc Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 39.25 M, a 229.25% change year over year.
Adicet Bio Inc Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 11.92 M, a 105.88% change year over year.
Adicet Bio Inc Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2020 was USD -202.84 M, a 70.36% change year over year.

NASDAQ: ACET

Adicet Bio Inc

CEO	Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
IPO Date	Jan. 26, 2018
Location	United States
Headquarters	200 Clarendon Street, Boston, MA, United States, 02116
Employees	143
Sector	Healthcare
Industry	Biotechnology

Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Key trends